Agena Biosciences

46 articles with Agena Biosciences

• Agena Bioscience® and Manchester University Announce Partnership to Provide Educational Resources to the Pharmacogenomics Industry

  11/29/2021

  Agena Bioscience®, a global provider of genetic testing solutions, announced a partnership with Manchester University to expand awareness and access to PGx educational resources.

• Mesa Labs Closes Acquisition of Agena Bioscience

  10/20/2021

  Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that it has completed the previously announced acquisition of Agena Biosciences, Inc.

• Mesa Labs Announces Agreement to Acquire Agena Bioscience, Inc.

  9/14/2021

  Mesa Laboratories, Inc., a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, announced that it has entered into a definitive agreement to acquire Agena Bioscience, Inc. for a cash purchase price of $300 million, subject to customary purchase price adjustments.

• Agena Bioscience Signs Exclusive Distribution Agreement with AGBL Group of Companies

  3/10/2021

  Agena Bioscience®, the global manufacturer of the MassARRAY® System for targeted genetic analysis, announced an exclusive distribution agreement with Alliance Global, the AGBL Group of companies, to bring the MassARRAY technology to many emerging markets across the Middle East, Africa, and Central Asia.

• Agena Bioscience Launches New Panel for Detection and Discrimination of SARS-CoV-2 Variants of Concern

  3/1/2021

  Agena Bioscience®, a global provider of low-cost, high-throughput molecular testing solutions, announced the launch of the MassARRAY® SARS-CoV-2 Variant Panel for the detection of key SARS-CoV-2 virus strains, including the UK, South Africa, Brazil and Denmark variants.

• Agena Bioscience Granted EUA for High-Throughput, Low-Cost SARS-CoV-2 Panel

  10/28/2020

  Agena Bioscience®, a global provider of low-cost and high-throughput molecular testing solutions, announced that its MassARRAY® SARS-CoV-2 Panel for qualitative detection of the SARS-CoV-2 coronavirus has been granted Emergency Use Authorization from the U.S. Food and Drug Administration.

• Agena Bioscience Announces EUA for High-Throughput, Low-Cost SARS-CoV-2 Panel

  6/16/2020

  Agena Bioscience, a global provider of low cost and high-throughput molecular testing solutions, announced the launch of the iPLEX® Pro SARS-CoV-2 Panel for qualitative detection of the novel coronavirus that causes COVID-19.

• Agena Improves PGx Testing Accuracy with Launch of VeriDose™ CYP2D6 CNV Panel to Detect Hybrid Alleles

  11/4/2019

  The RUO panel quantifies CYP2D6 copy number, even in the presence of CYP2D6/CYP2D7 hybrid alleles which cannot be detected by commonly used PGx technologies.

• Agena Launches Bone Marrow Engraftment Assay For Chimerism Analysis

  11/1/2018

  Agena Bioscience, a global provider of molecular testing solutions, today announced the release of the Chimeric ID Panel designed to reduce the time and cost of performing chimerism analysis for bone marrow engraftment monitoring studies.

• Agena And DaRui Biotechnology Announce China FDA Clearance Of MassARRAY Technology For Diagnostic Use In China

  10/24/2018

  Commercially branded in China as DR MassARRAY by DaRui, the approval of the MALDI-TOF based system for targeted genetic analysis is the successful culmination of the commercial partnership that was initiated in 2016 between the two companies.

• Agena Bioscience Announces Collaboration With PerkinElmer

  8/21/2018

  Combining LabChip® GX Touch Nucleic Acid Analyzer and MassARRAY® for Optimized Liquid Biopsy Workflow

• Agena Announces MassARRAY Technology Selected For Participation In CANCER-ID Consortium

  7/24/2018

  Agena Bioscience announced today that it has been selected for participation in the CANCER-ID Consortium.

• Agena Announces MassARRAY Commercial Partnership Agreement With Dian For China Clinical Laboratory Market

  7/10/2018

  Agena Bioscience announced that it has entered into a commercial partnership agreement with Zhejiang Dian Diagnostics Co., Ltd.

• Agena Bioscience's Liquid Biopsy Technology Awarded Horizon 2020 Grant by European Union

  11/30/2017

  Agena Biosciences today announced it has been selected to participate as an innovative technology provider in the LIMA project.

• Agena Biosciences Bolsters MassARRAY Insights Reporting Network By Adding N-of-One

  10/5/2017

• Agena Biosciences Release: Highly Sensitive Assessment Of Common Somatic Mutations In Pulmonary Non-Small Cell Carcinoma With The MassARRAY System

  9/27/2017

• Agena Biosciences Announces Molecular Health As The First Interpretation Software Provider For MassARRAY Insights

  9/19/2017

• Agena Biosciences Release: MassARRAY System Selected For Illinois State Cystic Fibrosis Screening Of Newborns

  8/2/2017

• Agena Biosciences And HeartGenetics Announce Co-Marketing Alliance

  7/18/2017

• Agena Biosciences Launches CE-IVD System For Hospitals And Diagnostic Laboratories In Europe

  6/29/2017